4 Stocks Improving Performance Of The Health Care Sector

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 1 points (0.0%) at 15,277 as of Thursday, May 16, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,398 issues advancing vs. 1,509 declining with 138 unchanged.

The Health Care sector currently sits down 0.72 versus the S&P 500, which is down 0.10. A company within the sector that increased today was UnitedHealth Group ( UNH), up 0.54. On the negative front, top decliners within the sector include Biomarin Pharmaceutical ( BMRN), down 6.00, Alexion Pharmaceuticals ( ALXN), down 4.57, Bristol-Myers Squibb Company ( BMY), down 3.51, Vertex Pharmaceuticals ( VRTX), down 3.07 and Gilead ( GILD), down 3.16.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector higher today:

4. Aegerion Pharmaceuticals ( AEGR) is one of the companies pushing the Health Care sector higher today. As of noon trading, Aegerion Pharmaceuticals is up $9.19 (19.57) to $56.16 on heavy volume Thus far, 1.8 million shares of Aegerion Pharmaceuticals exchanged hands as compared to its average daily volume of 541,500 shares. The stock has ranged in price between $47.45-$57.34 after having opened the day at $47.45 as compared to the previous trading day's close of $46.97.

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases in the United States. Aegerion Pharmaceuticals has a market cap of $1.4 billion and is part of the drugs industry. Shares are up 87.6% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Aegerion Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Aegerion Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Aegerion Pharmaceuticals Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

5 Stocks Insiders Love Right Now

7 Stocks Under $10 Making Big Up Moves

5 Stocks Under $10 Set to Soar

Wall Street Loses Gains After Fed's Unsurprising June Call

Stocks Turn Lower After Yellen Expresses Confidence in U.S. Economy